AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MARECHALE CAPITAL PLC

Interim / Quarterly Report Jan 29, 2018

7775_ir_2018-01-29_2faa1dd7-ef50-4ed5-a33d-81c762d15afb.html

Interim / Quarterly Report

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1140D

Marechale Capital PLC

29 January 2018

29 January 2018

Marechale Capital plc

("Marechale Capital" or the "Company")

Interim Results

Marechale Capital plc today announces its unaudited interim results for the six months ended 31 October 2017.

Chairman's Statement

Marechale Capital has had a challenging half year since we reported our final results back in July. Further to the trading update announcement on the 9th November, I report that revenues for the six months of £125,000 (2016 £531,000) are below budget and that the Company has made a loss of £460,000 (2016: profit £10,000) after making a provision against the fair value of options held in investee companies of £118,500 (2016: £100), and after making a second provision against the carrying value of our Associate Company, Northfield UK Solar Ltd ('NUKS'), of £63,000.

The fall in revenues is largely due to delays in a number of the transactions we are involved in, although I am pleased to be able to report that we have recently closed a transaction for a leisure sector client which generated a fee of around £300,000.  Whilst our deal flow remains strong, it is still taking longer to complete transactions.

One of Marechale Capital's key strategies is the achievement of growth in net asset value generated from options and investments in client and partner companies. Unfortunately, NUKS and Future Biogas Limited have diminished significantly in value recently, resulting in the write-downs referred to above.

In light of the above, the Board of Marechale Capital continues to consider its options.

Mark Warde-Norbury

Chairman

For further information please contact:

Marechale Capital

Mark Warde-Norbury / Patrick Booth-Clibborn
Tel: +44 (0)20 7628 5582
Smith & Williamson Corporate Finance

Azhic Basirov / David Jones
Tel: +44 (0)20 7131 4000
Consolidated Income Statement (unaudited)
6 months ended 31 October 30 September
2017 2016
£ £
Revenue 125,066 530,872
Cost of sales (44,370) (152,816)
Gross profit 80,696 378,056
Administrative expenses (358,988) (364,432)
Operating (loss)/profit (278,291) 13,624
Investment revenues - -
Other (losses) (118,500) (73)
Net (loss) in respect of associate

Provision for project loss in associate


(63,000)
(3,448)

-
(Loss)/profit before tax (459,791) 10,103
Taxation - -
(Loss)/profit for the period (459,791) 10,103
(Loss)/profit per share (Pence) (Pence)
- Basic (0.007) 0.02
- Diluted (0.007) 0.02
Consolidated Balance Sheet (unaudited)
As at 31 October 30 September
2017 2016
£ £
Non current assets
Investment in associate 14,187 150,827
Current assets
Available for sale investments 153,341 166,347
Trading investments 78,388 131,800
Trade and other receivables 69,894 260,564
Cash and cash equivalents 98,110 218,540
399,734 777,251
Total assets 413,921 928,079
Current liabilities
Trade and other payables (125,596) (102,363)
Total current liabilities (125,596) (102,363)
Net assets 288,325 825,716
Equity
Capital and reserves attributable to equity shareholders
Share capital 461,449 2,474,308
Share premium account - 1,247,379
Revaluation reserve 81,826 94,326
Reserve for own shares (50,254) (50,254)
Retained losses (289,150) (2,940,043)
Reserve for share based payments 84,453 -
288,325 825,716
Consolidated Cash Flow Statement (unaudited)
6 months ended 31 October 30 September
2017 2016
£ £
Net cash from operating activities
Operating (loss) / profit (278,291) 13,624
Provision for share based payments - 17,500
Operating cash flows before movements in working capital (278,291) 31,124
Movement in working capital
Decrease in receivables 151,781 258,013
(Decrease) in payables (77,755) (281,013)
74,026 (23,000)
Operating cash flow (204,265) 8,124
Investment activities
Interest (payable)/receivable - (73)
Proceeds on disposal of trading investments - -
Proceeds on disposal of available for sale investments - -
Expenditure on available for sale investments - -
Cash flow from investing activities - (73)
Financing
Issue of share capital - -
Interest payable - -
Cash flow from financing activities - -
Net (decrease)/ increase in cash and cash equivalents (204,265) 8,050
Cash and cash equivalents at start of the period 302,375 210,490
Cash and cash equivalents at end of the period 98,110 218,540
(Decrease)/increase in cash and cash equivalents (204,265) 8,050

This financial information has been prepared in accordance with IFRS and International Financial Reporting Interpretations Committee ('IFRIC') interpretations adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS, with the prior period being reported on the same basis.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IR FKADPABKDFDB

Talk to a Data Expert

Have a question? We'll get back to you promptly.